The research highlights the necessity of a multifaceted approach, incorporating a tumor-antigen-targeting antibody, a modified interleukin-2 with extended half-life, anti-PD-1, and a potent T cell vaccine, to effectively mobilize both innate and adaptive immune mechanisms against the tumor (13). Here, IL2 is linked to neoplasm.